Last updated: May 26, 2026
Ceftazidime supply chains split into (1) active pharmaceutical ingredient (API) manufacturers and (2) finished-dose producers (sterile injectables). In practice, hospitals and distributors source ceftazidime via global generic injectables makers and contract manufacturing networks, with API sourced from a smaller set of specialty antibiotic and sterile-injectable suppliers.
Who supplies ceftazidime API and finished injectable products?
Short answer: Ceftazidime is supplied as an injectable antibiotic via licensed sterile manufacturers and wholesalers. API is produced by antibiotic API plants and then finished-dose sterile manufacturers formulate and aseptically fill ceftazidime products.
API suppliers for ceftazidime
Ceftazidime API is typically manufactured in facilities that support beta-lactam antibiotic chemistry and controlled impurity profiles (including stereochemical and degradation impurity management). API supply is concentrated in contract and specialty antibiotic API producers that also service multiple cephalosporins.
Finished-dose suppliers for ceftazidime
Finished ceftazidime is supplied primarily as:
- Powder for injection (reconstituted with sterile diluent)
- Sterile vials for hospital dispensing
- Pre-filled formats in some markets (less common)
Finished-dose supply is dominated by global sterile injectable manufacturers and antibiotic-focused generic injectables producers that can operate aseptic filling, lyophilization or controlled drying (where relevant), and vial closure validation.
Which companies manufacture generic ceftazidime injection worldwide?
Short answer: Generic ceftazidime injectables are produced by multiple international firms across Europe, India, China, and other Asian supply hubs, with distribution through regional wholesalers and tenders.
Europe supply (typical structure)
- Generics enter via national authorizations and EU marketing authorizations for sterile injectables.
- Tender-driven purchasing favors multiple qualified suppliers to maintain continuity of supply.
U.S. supply (typical structure)
- Products are listed on FDA systems for registered finished doses.
- U.S. distribution uses domestic wholesalers plus international finished-dose imports.
Asia supply (typical structure)
- Several API and finished-dose producers operate export-oriented sterile and antibiotic manufacturing.
- Supply contracts are often tied to batch release timelines and antibiotic impurity control.
What are the ceftazidime dosage forms and who supplies each?
Ceftazidime products vary by marketed strength and presentation, which drives supplier qualification.
Common presentations
- Ceftazidime 250 mg, 500 mg, 1 g, 2 g vials
- Powder for reconstitution for IV or IM administration
Sterile manufacturing requirements that affect supplier qualification
- Aseptic processing controls
- Container-closure integrity
- Particle and endotoxin limits
- Robust batch release testing for beta-lactam degradation products
What are the largest ceftazidime finished-dose distributors?
Short answer: Finished ceftazidime is distributed through large pharmaceutical wholesalers and tender logistics providers in each market, with hospital procurement often awarding multiple suppliers.
Typical distribution chain
- Manufacturer (sterile finished-dose) → national distributor/wholesaler → hospital pharmacy or group purchasing organization
What determines which distributors carry ceftazidime
- Availability of local marketing authorization
- Contract capacity for sterile injectables
- Storage and cold-chain needs (if applicable for a given presentation)
- Bid competitiveness under government and hospital tender frameworks
How does supply continuity risk affect ceftazidime suppliers?
Short answer: Ceftazidime availability is sensitive to upstream antibiotic API capacity, beta-lactam plant utilization, and sterile injectable manufacturing throughput.
Key risk drivers
- API batch rejection due to impurity drift
- Sterile facility downtime or aseptic line constraints
- Regulatory hold points after deviations
- Demand surges in hospital settings during infection seasonality
What buyers do to mitigate risk
- Dual sourcing across at least two finished-dose manufacturers
- Contract clauses that define lead times and replacement supply triggers
What procurement strategy works for ceftazidime sourcing?
Short answer: Build a qualification matrix across API risk, sterile-dose capacity, and regulatory standing, then dual-source finished-dose product.
Qualification matrix (practical)
- Finished-dose manufacturer compliance history for sterile injectables
- Batch release timelines and distribution reliability
- Compatibility with hospital reconstitution workflows (vial format)
- Ability to support emergency replenishment allocations
Key Takeaways
- Ceftazidime supply is split between a narrower set of antibiotic API producers and a broader set of sterile finished-dose manufacturers.
- Finished-dose availability depends on sterile aseptic capacity and container-closure and quality controls for vials.
- Procurement continuity is strongest with dual sourcing across different finished-dose manufacturers and aligned distribution contracts.
FAQs
1) Who makes ceftazidime injection in the European market?
Generic ceftazidime injectables are supplied by multiple EU-authorized sterile manufacturers that sell through national distributors and hospital tender channels.
2) Are ceftazidime API and ceftazidime injection supplied by the same company?
Often not. API production is usually handled by specialty antibiotic API plants, while injection manufacturing is handled by sterile finished-dose manufacturers.
3) What are the most common ceftazidime vial strengths?
Typical marketed strengths include 250 mg, 500 mg, 1 g, and 2 g for reconstitution-based IV/IM administration.
4) What causes ceftazidime supply shortages?
Upstream API capacity disruptions, sterile line constraints, batch release failures, and regulatory holds are common drivers in antibiotic supply markets.
5) How can hospitals reduce ceftazidime stockout risk?
Dual sourcing finished-dose products across separate manufacturers and maintaining supplier contracts with emergency replenishment terms.
References
No sources were provided in the prompt, and no supplier-identifying sources can be cited without external input.
